What did the prespecified analysis show, and how do the full safety results affect interpretation?
YOUR PRIVATE STARTING POINT
Compare with what you saved.
Save a milestone to your account’s Notebook. Reopen its original snapshot here and compare with this reviewed catalog. Email subscriptions use a separate opt-in.
Lilly expected the confirmatory TRAILBLAZER-ALZ 2 topline readout in Q2 2023. The announcement separately described a complete response letter for the earlier accelerated-approval application; those are different events.
Lilly announced Phase 3 topline results and reported meeting the primary endpoint. The release also described serious amyloid-related imaging abnormalities, including deaths; the readout is not a blanket safety claim.
These selected company announcements preserve publication dates separately from ORION’s later recording times. Registry completion dates and follow-up research questions are separate from company announcements; this historical release does not establish current guidance or continuous monitoring.